Toulose, France Clinical Trials

A listing of Toulose, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 133 clinical trials
Perioperative Eltrombopag in Patients With Inherited Thrombocytopenia

The objective of the study is to estimate the response to eltrombopag based on platelet count increase above a safety level of 80 G/L and lack of requirement for pre-, per- and post-operative administration of platelet concentrates (PC) for performing elective invasive acts at mild or high bleeding risk,in selected …

Bordeaux Hospital
 (131.2 away) Contact site
  • 26 Jan, 2021
  • +22 other locations
Topical Sirolimus in Cutaneous Lymphatic Malformations

Cutaneous microcystic lymphatic malformations (CMLMs) are rare conditions of children and adults resulting from abnormal embryologic development of lymphatic vessels. They present as clusters of vesicles full of lymph and blood of various extent. They ooze and bleed, inducing maceration, esthetic impairment, scars, pain, bacterial infections and impaired quality of …

 (121.2 away) Contact site
  • 27 Jan, 2021
  • +14 other locations
Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma

This study is a prospective open label, multicenter, phase II, window-of-opportunity preoperative, single-agent trial. This study aims to evaluate the efficacy, the safety and tolerability profile of bintrafusp alfa in patients with histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, previously untreated, with …

Institut Claudius R gaud
 (0.5 away) Contact site
  • 03 Apr, 2021
  • +7 other locations
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

For patients with advanced/metastatic gastric adenocarcinomas in progression after a first line chemotherapy comprising platinum and fluoropyrimidine, the reported second line treatments are : 1) paclitaxel combined with ramucirumab (overall response rate (ORR) = 25%; median progression free survival (PFS) = 2.9 months; median overall survival (OS)= 5.9 months), or …

Bordeaux - Hopital Haut-Leveque
 (131.6 away) Contact site
  • 06 Apr, 2021
  • +7 other locations
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

This study is a multicenter phase II trial including 2 cohorts of patients in Refractory/Relapse disease at least 1 month after CAR T-cells therapy: cohort 1: DLBCL patients cohort 2: PMBL, mantle cell lymphoma, transformed indolent NHL (t-iNHL) or iNHL CAR T-cells Refractory/Relapse status will be determined by PET-CT central …

CHU Montpellier
 (122.5 away) Contact site
  • 21 Jun, 2021
  • +14 other locations
Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Basket trial concept to independently and simultaneously assess the effects of the association of atezolizumab + BDB001 + radiotherapy in multiple solid tumors.

Institut du Cancer de Montpellier
 (119.3 away) Contact site
  • 16 May, 2021
  • +9 other locations
BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS

To assess the efficacy, and safety of BST-236 in patients unfit for intensive chemotherapy with AML or HR MDS that failed or relapsed following first line therapy

ejection fraction
carbon monoxide
refractory acute myeloid leukemia (aml)
CHU Toulouse - IUCT Oncopole
 (3.8 away) Contact site
  • 16 Jun, 2021
  • +14 other locations
Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

NEONEC is a single-phase, phase II study evaluating the efficacy of the 12-month neoadjuvant chemotherapy in patients with locally differentiated digestive NEC. The recommended chemotherapy is based on the current reference combination of platinum (cisplatin or carboplatin) and etoposide (VP16). For anorectal locations, radiochemotherapy is proposed to avoid the morbidity …

ct scan
who 2017
CHU Toulouse
 (0.0 away) Contact site
  • 22 Jun, 2021
  • +8 other locations
ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients

Study of early administration of ASTX727 associated with late Donor Lymphocyte Infusions after allogenic stem cell transplantation in very high risk MDS or AML patients

blast cells
cell transplantation
IUCT Oncopole - D partement d'h matologie - Service de greffe de cellules souches h matopo tiques
 (2.3 away) Contact site
  • 26 Jul, 2021
  • +13 other locations
Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients

This is a randomized, double-blinded, 2 arms study concerning patients with high-grade bone sarcoma (HGBS) without complete remission after standard treatment at diagnosis or first relapse. In the first arm, patients will be treated with regorafenib + best supportive care (BSC) for a maximum of 12 months as maintenance therapy …

neutrophil count
progressive disease
glomerular filtration rate
ICM Val d'Aurelle
 (121.2 away) Contact site
  • 07 Aug, 2021
  • +13 other locations